Trial · NCT01134055
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS) Grading Charts at a Starting Distance of 4 Meters at Week 52 | Day 1 and 52 weeks | Intent to Treat Population - It consisted of all randomized participants, according to the treatment groups assigned by randomization (i.e., planned rather than the actual treatment regimen), who received at least one dose of study medication. Only participants with data available at the indicated time points were analyzed. | Letters | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Up to 52 weeks | Intent to Treat Population | Percentage of re-injections | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants With BCVA Over Time | Up to Week 52 | Intent to Treat Population. Only participants with data available at the indicated time points were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Analyzed for Visual Acuity (VA) Response Over Time | Week 52 | Intent to Treat Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in Center Point Thickness (CPT) Over Time | Baseline and Week 52 | Intent to Treat Population | Microns | MEAN |
| SECONDARY | Number of Participants That Met Criteria for Re-injection | Up to Week 52 | Intent to Treat Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in the Area of Choroidal Neovascularisation (CNV) | Day 1, Week 28 and Week 52 | Intent to Treat Population | Millimeter (mm)^2 | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Area of the CNV Lesion Complex (i.e. CNV, Blood, PED, and Fibrosis) | Day 1, Week 28 and Week 52 | Intent to Treat Population | mm^2 | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Area of Fluorescein Leakage | Day 1, Week 28 and Week 52 | Intent to Treat Population | mm^2 | LEAST_SQUARES_MEAN |
| SECONDARY | Change in Area of Serous Sensory Retinal Detachment (SSRD) | Day 1, Week 28 and Week 52 | Intent to Treat Population | mm^2 | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 52 Weeks | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Summary of Potentially Clinically Important Findings for Ophthalmic Examinations | Up to Week 52 | Safety population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Summary of Intraocular Pressure Exam Findings | Up to week 52 | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Vital Sign Values Outside of Clinical Concern Range | Up to Week 52 | Safety Population. Only participants with data available at the indicated time points were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Summary of Abnormal Electrocardiogram (ECG) Findings | Week 4, Week 28, Week 44 and Week 52 | Safety population. Only participants with data available at the indicated time points were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Summary of Hematology and Clinical Chemistry Parameters Data of Clinical Concern | Up to Week 52 | Safety Population. Only participants with data available at the indicated time points were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Laboratory Data of Clinical Concern for Urine Protein | Day 1 to Week 28 and Week 52 | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Plasma Concentrations of Pazopanib | Week 4, Week 24 and Week 52 | Safety Population. Only participants with data available at the indicated time points were analyzed. | nanogram/milliliter | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01134055/outcomes